HONG KONG, Sept 10, 2019 - (ACN Newswire) - Aptorum Group
Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical
company focused on the development of novel therapeutics to address
global unmet medical needs, announces the development of two
preclinical drug candidates which target obesity and neuroblastoma,
respectively.
About CLS-1: Treatment of obesity via modulation of chemical
signaling relating to gut microbiota
Under the recently-announced microbiota modulation platform
operated by Aptorum Group's wholly-owned subsidiary Claves Life
Sciences Limited, we have commenced the preclinical development of
macromolecule candidate CLS-1 targeting the treatment of obesity.
CLS-1 is undergoing lead optimization and is expected to progress
into the IND enabling stage in 2020.
The prevalence of obesity continues to escalate globally; however,
there is no current optimal therapy for this condition1. For the
majority of obese patients, conventional medical therapies (i.e.,
diet, exercise, behavioral counseling) often have a high failure
rate for the long term2. We believe current pharmacotherapy has
limited efficacy and is associated with substantial safety issues,
and this will provide immeasurable market opportunity for
CLS-1.
Chemical signaling of gut microbiota is known to be one of the
major causes of obesity1. CLS-1 is an orally administered
non-absorbable macromolecule that modulates the metabolite excreted
by gut microbiota with high affinity and specificity. In this way,
we believe the absorption of this particular metabolite, which is
linked to obesity, can be inhibited.
Aptorum Group is also pursuing two further indications based on the
modulation of microbiota based chemical signaling involving the
above large molecule technology, which we believe to be highly
scalable and we hope to be making further announcements regarding
our efforts in due course.
About SACT-1: Repurposed Drug Candidates for the Treatment of
Neuroblastoma
Under the recently announced Smart-ACTTM computational drug
discovery platform operated by our wholly-owned subsidiary Smart
Pharma Group, Aptorum Group has completed computational screening
of approximately 1,615 marketed drugs against 3 therapeutic target
proteins to potentially tackle poor prognosis of neuroblastoma,
i.e., a rare type of children's cancer that forms in certain types
of nerve tissue and most frequently in the adrenal glands as well
as spine, chest, abdomen or neck, especially in children3. For the
high-risk group, the 5-year survival rate of this condition is
around 40-50% as observed by the American Cancer Society.4 Aptorum
Group has identified an array of repurposed candidates and has
proceeded to evaluate them in cell-based and animal models in order
to validate the candidates' usage for such new indication and
potential efficacies.
Aptorum Group is also pursuing two further indications under the
Smart-ACTTM drug discovery platform and hopes to be making further
announcements regarding our research in due course.
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company
dedicated to developing and commercializing novel therapeutics to
tackle unmet medical needs. Aptorum Group is pursuing therapeutic
projects in neurology, infectious diseases, gastroenterology,
oncology and other disease areas.
For more information about Aptorum Group, please visit
www.aptorumgroup.com.
About Claves Life Sciences Limited
Claves Life Sciences Limited is a wholly-owned therapeutics
subsidiary of Aptorum Group Limited. Claves focuses on the clinical
development of therapeutic candidates related to the field of
gastroenterology. The potential candidates under review and
potentially developed focus on the modulation of gut
microbiota-derived metabolites, for the prevention or treatment of
diseases. Claves is also exploring a gut microbiota modulation
platform that can generate novel customized candidates capable of
fine-tuning levels of gut metabolites, potentially treating a wide
range of medical conditions.
About Smart Pharma Group
Smart Pharma Group includes Smart Pharmaceutical Limited
Partnership, SMTPH Limited and its subsidiaries. The Smart Pharma
Group is wholly owned by Aptorum Group Limited. Smart Pharma Group
focuses on systematically repurposing existing approved drugs for
the treatment of a large array of orphan diseases. Smart Pharma
Group conducts both computational based screening and preclinical
validations in advancing the development of its repurposed
candidates.
For more information about Smart Pharma Group, please visit
www.smtph.com.
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. For this purpose,
any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as "may," "should," "expects," "plans," "anticipates,"
"could," "intends," "target," "projects," "contemplates,"
"believes," "estimates," "predicts," "potential," or "continue," or
the negative of these terms or other similar expressions. Aptorum
Group has based these forward-looking statements, which include
statements regarding projected timelines for application
submissions and trials, largely on its current expectations and
projections about future events and trends that it believes may
affect its business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued
service and availability of key personnel, its ability to expand
its product assortments by offering additional products for
additional consumer segments, development results, the company's
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum
Group's Form 20-F and other filings that Aptorum Group may make
with the SEC in the future. As a result, the projections included
in such forward-looking statements are subject to change. Aptorum
Group assumes no obligation to update any forward-looking
statements contained in this press release as a result of new
information, future events or otherwise.
1 Protein Cell. May; 9(5): 397-403.
2 Obes Surg. 2012 Jun;22(6):956-66
3
https://www.cancer.gov/publications/dictionaries/cancer-terms?expand=N
4 See
https://www.cancer.org/cancer/neuroblastoma/detection-diagnosis-staging/survival-rates.html.
Contacts
Investors:
Tel: +852 2117 6611
Email: investor.relations@aptorumgroup.com
Media:
Tel: + 852 2117 6611
Email: info@aptorumgroup.com
Kindly refer to the below link for our corporate presentation:
https://aptorumgroup.gcs-web.com/static-files/bcf77574-7bd6-4b9d-8110-d53837238f16
You may also refer to the below for our one-pager presentation:
https://aptorumgroup.gcs-web.com/static-files/9347f385-d6c9-489d-af0a-ddcbbec002f1
Copyright 2019 ACN Newswire . All rights reserved. |